Back to Search
Start Over
Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach.
- Source :
-
The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2016 Nov; Vol. 17 (8), pp. 991-999. Date of Electronic Publication: 2015 Nov 24. - Publication Year :
- 2016
-
Abstract
- Purpose: The direct cost to the National Health Service (NHS) in England of pars plana vitrectomy (PPV) is unknown since a bottom-up costing exercise has not been undertaken. Healthcare resource group (HRG) costing relies on a top-down approach. We aimed to quantify the direct cost of intermediate complexity PPV.<br />Methods: Five NHS vitreoretinal units prospectively recorded all consumables, equipment and staff salaries during PPV undertaken for vitreomacular traction, epiretinal membrane and macular hole. Out-of-surgery costs between admission and discharge were estimated using a representative accounting method.<br />Results: The average patient time in theatre for 57 PPVs was 72 min. The average in-surgery cost for staff was £297, consumables £619, and equipment £82 (total £997). The average out-of-surgery costs were £260, including nursing and medical staff, other consumables, eye drops and hospitalisation. The total cost was therefore £1634, including 30 % overheads. This cost estimate was an under-estimate because it did not include out-of-theatre consumables or equipment. The average reimbursed HRG tariff was £1701.<br />Conclusions: The cost of undertaking PPV of intermediate complexity is likely to be higher than the reimbursed tariff, except for hospitals with high throughput, where amortisation costs benefit from economies of scale. Although this research was set in England, the methodology may provide a useful template for other countries.<br />Competing Interests: Compliance with ethical standards Conflicts of interest Some of the results from this research were presented at the International ISPOR Conference in New Orleans, May 2013. Thrombogenics provided funding to undertake this study, including financial support to attend the ISPOR Conference. T.J. is a Consultant to Bausch and Lomb, and Thrombogenics and a paid speaker for DORC.
Details
- Language :
- English
- ISSN :
- 1618-7601
- Volume :
- 17
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- The European journal of health economics : HEPAC : health economics in prevention and care
- Publication Type :
- Academic Journal
- Accession number :
- 26603298
- Full Text :
- https://doi.org/10.1007/s10198-015-0741-6